Condition: Brain Tumor · Grade III Glioma · Grade IV Glioma · Sponsor: NanoAlvand
This is a phase IV, post-marketing, observational, cohort study for safety and effectiveness evaluation of Amitzo® in Iranian patients with grade III and IV glioma tumors. No control group is considered in the study design. The primary objective is to evaluate the incidence of hepatic injury in patients with grade III and IV glioma tumors, treated with Amitzo®.
This description comes directly from the study's public registry record.
Nassim Anjidani, PharmD · +982143473000 · anjidani.n@orchidpharmed.com
Always discuss trial participation with your own doctor first.
| Orchid Pharmed | Tehran, Iran | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07675070